BACKGROUND: Streptococcus pneumoniae-associated hemolytic uremic syndrome (P-HUS) is a rare and severe disease. Only a few reports have been published about eculizumab use in P-HUS. METHODS: We analyzed demographic, clinical, and laboratory data of patients with P-HUS from our center. RESULTS: The cohort consisted of 4 females and 3 males. All patients had pneumonia. Four were given eculizumab (days 1-3). The eculizumab group required a shorter duration of dialysis and mechanical ventilation (medians 20 vs. 28.5 and 30 vs 38.5 days, respectively) compared with the non-eculizumab group, but this was still much longer than normally reported; the thrombocytopenia resolution was similar in both groups (medians 10 vs. 8 days). Chronic kidney disease (CKD) was correlated with the duration of dialysis and mechanical ventilation duration at 1 year (r = 0.797, P = 0.032 and r = 0.765, P = 0.045) and last follow-up (r = 0.807, P = 0.028 and r = 0.814, P = 0.026, respectively); our scoring system showed even stronger correlations (r = 0.872, P = 0.011 and r = 0.901, P = 0.0057, respectively). The eculizumab group showed slightly better 1-year and last follow-up CKD stage (2.75 vs. 3, P = 0.879 and 2.5 vs. 3.67, P = 0.517). CONCLUSIONS: Despite the fact that the eculizumab group showed better outcomes, eculizumab does not seem to improve the course of P-HUS compared with previous reports. Kidney outcomes are strongly correlated with the duration of dialysis and mechanical ventilation duration. A higher resolution version of the Graphical abstract is available as Supplementary information.

Department of Pediatric Nephrology 2nd Faculty of Medicine University Hospital Motol Charles University Prague Czech Republic

Pediatrická Klinika 2 LF UK and FN v Motole 5 Úvalu 84 Prague 5 15006 Czech Republic

See more in PubMed

Scobell RR, Kaplan BS, Copelovitch L. New insights into the pathogenesis of Streptococcus pneumoniae-associated hemolytic uremic syndrome. Pediatr Nephrol. 2020;35:1585–1591. doi: 10.1007/s00467-019-04342-3. PubMed DOI

Fakhouri F, Zuber J, Frémeaux-Bacchi V, Loirat C. Hemolytic uremic syndrome. Lancet. 2017;390:681–696. doi: 10.1016/S0140-6736(17)30062-4. PubMed DOI

Waters AM, Kerecuk L, Luk D, Haq MR, Fitzpatrick MM, Gilbert RD, Inward C, Jones C, Pichon B, Reid C, Slack MP, Van't Hoff W, Dillon MJ, Taylor CM, Tullus K. Hemolytic uremic syndrome associated with invasive pneumococcal disease: the United Kingdom experience. J Pediatr. 2007;151:140–144. doi: 10.1016/j.jpeds.2007.03.055. PubMed DOI

Copelovitch L, Kaplan BS. Streptococcus pneumoniae-associated hemolytic uremic syndrome: classification and the emergence of serotype 19A. Pediatrics. 2010;125:e174–e182. doi: 10.1542/peds.2007-2017. PubMed DOI

Banerjee R, Hersh AL, Newland J, Beekmann SE, Polgreen PM, Bender J, Shaw J, Copelovitch L, Kaplan BS, Shah SS, Emerging Infections Network Hemolytic-Uremic Syndrome Study Group Streptococcus pneumoniae-associated hemolytic uremic syndrome among children in North America. Pediatr Infect Dis J. 2011;30:736–739. doi: 10.1097/INF.0b013e3182191c58. PubMed DOI

Szilágyi A, Kiss N, Bereczki C, Tálosi G, Rácz K, Túri S, Györke Z, Simon E, Horváth E, Kelen K, Reusz GS, Szabó AJ, Tulassay T, Prohászka Z. The role of complement in Streptococcus pneumoniae-associated hemolytic uremic syndrome. Nephrol Dial Transplant. 2013;28:2237–2245. doi: 10.1093/ndt/gft198. PubMed DOI

Gómez Delgado I, Corvillo F, Nozal P, Arjona E, Madrid Á, Melgosa M, Bravo J, Szilágyi Á, Csuka D, Veszeli N, Prohászka Z, Sánchez-Corral P. Complement genetic variants and FH desialylation in S. pneumoniae-hemolytic uremic syndrome. Front Immunol. 2021;12:641656. doi: 10.3389/fimmu.2021.641656. PubMed DOI PMC

Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20:629–637. doi: 10.1681/ASN.2008030287. PubMed DOI PMC

See J, BouMatar R, Baloglu O, Latifi SQ, Talati R, Agarwal HS. Early initiation of eculizumab therapy for Streptococcus pneumoniae-associated hemolytic uremic syndrome. Pediatr Blood Cancer. 2021;68:e28589. doi: 10.1002/pbc.28589. PubMed DOI

Jeantet G, Pernin V, Brunot V, Roccabianca A, Macombe A, Szwarc I, Klouche K, Loirat C, Mourad G, Frémeaux-Bacchi V, Le Quintrec M. Successful treatment of a Streptococcus pneumoniae-associated hemolytic uremic syndrome by eculizumab. Clin Kidney J. 2019;12:106–109. doi: 10.1093/ckj/sfy019. PubMed DOI PMC

Gilbert RD, Nagra A, Haq MR. Does dysregulated complement activation contribute to hemolytic uremic syndrome secondary to Streptococcus pneumoniae? Med Hypotheses. 2013;81:400–403. doi: 10.1016/j.mehy.2013.05.030. PubMed DOI

Holle J, Habbig S, Gratopp A, Mauritsch A, Müller D, Thumfart J. Complement activation in children with Streptococcus pneumoniae associated hemolytic uremic syndrome. Pediatr Nephrol. 2021;36:1311–1315. doi: 10.1007/s00467-021-04952-w. PubMed DOI PMC

Huang YH, Lin TY, Wong KS, Huang YC, Chiu CH, Lai SH, Hsia SH. Hemolytic uremic syndrome associated with pneumococcal pneumonia in Taiwan. Eur J Pediatr. 2006;165:332–335. doi: 10.1007/s00431-005-0041-8. PubMed DOI

Prestidge C, Wong W. Ten years of pneumococcal-associated hemolytic uremic syndrome in New Zealand children. J Paediatr Child Health. 2009;45:731–735. doi: 10.1111/j.1440-1754.2009.01603.x. PubMed DOI

Spinale JM, Ruebner RL, Copelovitch L, Kaplan BS. Long-term outcomes of Shiga toxin hemolytic uremic syndrome. Pediatr Nephrol. 2013;28:2097–2105. doi: 10.1007/s00467-012-2383-6. PubMed DOI